Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2131-2136

  Hainsworth, John D ^a   Spigel, David R ^a   Burris III, Howard A ^a   Waterhouse, David ^a   Clark, Bobby L ^a   Whorf, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77952301116     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3152     Document Type: Article

References (17)

1. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
2. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
3. Escudier BJ, Bellmunt J, Negrier S, et al: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:239s, 2009 (suppl; abstr 5020)
4. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
5. Motzer RJ, Escudier B, Oudard S, et al: RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol 26:256s, 2008 (suppl; abstr LBA5026)
6. Zafar Y, Bendell J, Lager J, et al: Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. J Clin Oncol 24:145s, 2006 (suppl; abstr 3097)
7. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
8. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003 (Pubitemid 36910021)
9. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002 (Pubitemid 34032623)
11. Sternberg CN, Szczylik C, Lee E, et al: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27:240s, 2009 (suppl; abstr 5021)
12. Feldman DR, Baum MS, Ginsberg MS, et al: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432-1439, 2009
13. Sosman JA, Flaherty KT, Atkins MB, et al: Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 26:252s, 2008 (suppl; abstr 5011)
14. Bukowski RM, Kabbinavar FF, Figlin RA, et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536-4541, 2007 (Pubitemid 350035309)
15. Shepard DR, Rini BI, Garcia JA, et al: A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26:280s, 2008 (suppl; abstr 5123)
16. Rini BI, Wilding GT, Hudes G, et al: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25:242s, 2007 (suppl; abstr 5032)
17. Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748, 2008